{
    "clinical_study": {
        "@rank": "67370", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Determine the long-term efficacy and safety of L-cysteine in the prevention\n      photosensitivity in patients with erythropoietic protoporphyria."
        }, 
        "brief_title": "Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria", 
        "completion_date": "May 1996", 
        "condition": "Erythropoietic Protoporphyria", 
        "condition_browse": {
            "mesh_term": "Protoporphyria, Erythropoietic"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a phase III study, lasting 3 years; 1996-1999. Patients are\n      administered L-cysteine orally twice daily, 2 capsules with breakfast and 2 with lunch.\n\n      Patients fill in questionnaires and diary sheets about their reaction to sunlight exposure,\n      and have blood tested 3 times a year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Erythropoietic protoporphyria RBC protoporphyrin greater than 50 micrograms/100 dL\n\n        --Prior/Concurrent Therapy--\n\n        At least 3 months since prior betacarotene or L-cysteine\n\n        No concurrent betacarotene\n\n        --Patient Characteristics--\n\n          -  Fertile female patients must use effective contraception for duration of trial and\n             for 3 weeks thereafter\n\n          -  Not pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "50", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004940", 
            "org_study_id": "199/13376", 
            "secondary_id": "BWH-FDR000996-DR"
        }, 
        "intervention": {
            "intervention_name": "cysteine hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "erythropoietic protoporphyria", 
            "inborn errors of metabolism", 
            "porphyria", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital", 
            "last_name": "Micheline Mary Mathews-Roth", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004940"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "May 1996", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2000"
    }, 
    "geocoordinates": {}
}